ABAL Abal Group Plc

RNS Number:9373O
Imaginatik PLC
28 February 2008



Imaginatik plc ("Imaginatik" or the "Company")

Pfizer Strategic Investment - Update

28 February 2008


The Company announced on 21 February 2008 that Pfizer Inc. ("Pfizer") had agreed
to subscribe for up to 12,953,368 new ordinary shares ("Subscription Shares").

The subscription price for a Subscription Share ("Subscription Price") and
number of Subscription Shares to be issued is based upon a 5% premium to the
average closing offer price of an ordinary share in Imaginatik over the five
dealing days following that announcement, being 21 February to 27 February 2008.
This Subscription Price has now been calculated as 6.22209 pence per
Subscription Share and Pfizer has subscribed for a total of 8,035,885
Subscription Shares representing 6.45 per cent. of the enlarged share capital.

Completion is conditional on admission to trading on AIM of the Subscription
Shares occurring on or by 13 March 2008 ("Admission").  Application for
Admission has been made today and is expected to occur on 6 March 2008.

Each Subscription Share will be issued credited as fully paid and free from all
liens, equities, charges, encumbrances and other interests and will upon their
issue rank in full for all dividends and distributions thereafter declared, made
or paid after Admission and shall  otherwise rank pari passu in all respects
with, and carry the same voting and dividend rights as, the existing ordinary
shares.

Pfizer  has also agreed not to dispose of its interest in the Subscription
Shares for a period of twelve months following Admission and for a subsequent
period of twelve months not to dispose of such interests other  than through
W.H. Ireland Limited or the Company's broker at the time, without in each case
the consent  of the Company, and save in each case in certain limited
circumstances.

Following the Subscription, the Company will have 124,637,111 ordinary shares in
issue.

The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company.



For further information please contact:

Imaginatik plc                                         Tel: +44 (0)20 7917 2975
Mark Turrell, CEO / Shawn Taylor, CFO

W.H. Ireland                                           Tel: +44 (0)121 265 6330
Tim Cofman/Katy Birkin

Investor relations and UK media                        Tel: +44 (0)20 7651 8688
ICIS
Tom Moriarty / Caroline Evans Jones

US media relations                                     Tel: +1 202-652-2250
Adam Dubitsky


About Imaginatik

Imaginatik is the leading provider of innovation and collaborative problem
solving software and process to the world's leading companies. More than 100
clients rely on Imaginatik's software, consulting and research to enable their
best-of-breed innovation activities.

Named as a World Economic Forum Technology Pioneer for 2008 and a finalist for
the IBM Lotus Awards 2008 in the Best Industry Solution category, Imaginatik's
software and consulting services have helped clients discover significant
sources of additional revenue, as well as tangible cost savings, process
improvements and increased product pipeline. Imaginatik is also committed to
developing strategic solutions in the field of innovation, working with academic
institutions such as the London Business School and the Cass School of Business,
London, as well as leading practitioners of corporate innovation.

For further information please visit http://www.imaginatik.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCKGGZZLRVGRZG

Abal (LSE:ABAL)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024

Abal (LSE:ABAL)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024